Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Deciphering the state of immune silence in fatal COVID-19 patients

Résumé : Since the beginning of the SARS-CoV-2 pandemic, COVID-19 has appeared as a unique disease with unconventional tissue and systemic immune features. While COVID-19 severe forms share clinical and laboratory aspects with various pathologies such as hemophagocytic lymphohistiocytosis, sepsis or cytokine release syndrome, their exact nature remains unknown. This is severely impeding the ability to treat patients facing severe stages of the disease. To this aim, we performed an in-depth, single-cell RNA-seq analysis of more than 150.000 immune cells isolated from matched blood samples and broncho-alveolar lavage fluids of COVID-19 patients and healthy controls, and integrated it with clinical, immunological and functional ex vivo data. We unveiled an immune signature of disease severity that correlated with the accumulation of naive lymphoid cells in the lung and an expansion and activation of myeloid cells in the periphery. Moreover, we demonstrated that myeloid-driven immune suppression is a hallmark of COVID-19 evolution and arginase 1 expression is significantly associated with monocyte immune regulatory features. Noteworthy, we found monocyte and neutrophil immune suppression loss associated with fatal clinical outcome in severe pa-tients. Additionally, our analysis discovered that the strongest association of the patients clinical outcome and immune phenotype is the lung T cell response. We found that patients with a robust CXCR6+ effector memory T cell response have better outcomes. This result is line with the rs11385942 COVID-19 risk allel, which is in proximity to the CXCR6 gene and suggest effector memory T cell are a primary feature in COVID-19 patients. By systemically quantifying the viral landscape in the lung of severe patients, we indeed identified Herpes-Simplex-Virus 1 (HSV-1) as a potential opportunistic virus in COVID-19 patients. Lastly, we observed an unexpectedly high SARS-CoV-2 viral load in an immuno-compromised patient, allowing us to study the SARS-CoV-2 in-vivo life cycle. The development of myeloid dysfunctions and the impairment of lymphoid arm establish a condition of immune paralysis that supports secondary bacteria and virus infection and can progress to immune silence in patients facing death.
Document type :
Preprints, Working Papers, ...
Complete list of metadatas

https://hal-pasteur.archives-ouvertes.fr/pasteur-02965308
Contributor : Benno Schwikowski <>
Submitted on : Tuesday, October 13, 2020 - 10:49:23 AM
Last modification on : Tuesday, October 20, 2020 - 3:28:34 AM

Links full text

Identifiers

Collections

Citation

Pierre Bost, Francesco de Sanctis, Stefania Cane, Stefano Ugel, Katia Donadello, et al.. Deciphering the state of immune silence in fatal COVID-19 patients. 2020. ⟨pasteur-02965308⟩

Share

Metrics

Record views

107